UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

American journal of kidney diseases, 2008-06, Vol.51 (6), p.904-913

2008

Volltextzugriff (PDF)

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

American journal of kidney diseases, 2005-03, Vol.45 (3), p.485-493

2005

Volltextzugriff (PDF)

Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans

Journal of clinical pharmacology, 2010-08, Vol.50 (8), p.914-921

2010

Volltextzugriff (PDF)

Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?

Journal of clinical pharmacology, 2014-09, Vol.54 (9), p.1038-1047

2014

Volltextzugriff (PDF)

Fenofibrate, homocysteine and renal function

Current vascular pharmacology, 2010-09, Vol.8 (5), p.589-603

2010

Volltextzugriff (PDF)

Fibrates and statins in the treatment of diabetic retinopathy

Current pharmaceutical biotechnology, 2011-03, Vol.12 (3), p.396-405

2011

Volltextzugriff (PDF)

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study

The lancet. Diabetes & endocrinology, 2018-04, Vol.6 (4), p.310-318

2018

Volltextzugriff (PDF)

Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers

Proteomics. Clinical applications, 2011-04, Vol.5 (3-4), p.159-166

2011

Volltextzugriff (PDF)

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease : The Diabetes Atherosclerosis Intervention Study (DAIS)

Circulation (New York, N.Y.), 2003-04, Vol.107 (13), p.1733-1737

2003

Volltextzugriff (PDF)

Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy

Current medical research and opinion, 2015-12, Vol.31 (12), p.2273-2285

2015

Volltextzugriff (PDF)

Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study

Ophthalmic epidemiology, 2014-10, Vol.21 (5), p.307-317

2014

Volltextzugriff (PDF)

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

Current therapeutic research, 2009-04, Vol.70 (2), p.71-93

2009

Volltextzugriff (PDF)

Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?

Current medical research and opinion, 2010-05, Vol.26 (5), p.1185-1192

2010

Volltextzugriff (PDF)

Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes

Diabetes care, 2002-03, Vol.25 (3), p.627-628

2002

Volltextzugriff (PDF)

Long-Term Effects of Fenofibric Acid + Statin Combination Therapy in Patients with High Triglycerides and Low HDL-C

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.228-228

2011

Volltextzugriff (PDF)

Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome: A Prospective, Randomized, Double-Blind, Three-Parallel Arm, Multicenter, Comparative Study

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009-01, Vol.9 (2), p.91-101

2009

Volltextzugriff (PDF)

Fibrates and microvascular complications in diabetes--insight from the FIELD study

Current pharmaceutical design, 2009-02, Vol.15 (5), p.537-552

2009

Volltextzugriff (PDF)

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

Atherosclerosis, 2003, Vol.166 (1), p.151-161

2003

Volltextzugriff (PDF)

LIPOPROTEIN SUBFRACTIONS ARE ASSOCIATED WITH ISCHEMIC STROKE AMONG 9,795 PATIENTS IN THE FIELD TRIAL

Journal of the American College of Cardiology, 2020-03, Vol.75 (11), p.2252-2252

2020

Volltextzugriff (PDF)

Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes

Future cardiology, 2006-11, Vol.2 (6), p.635-646

2006

Volltextzugriff (PDF)

Abstract WP219: Lipoprotein Subfractions Are Associated With Stroke Among 9,795 Patients in the Field Trial

Stroke (1970), 2020-02, Vol.51 (Suppl_1)

2020

Volltextzugriff (PDF)

41-LB: Lipoprotein Subfractions Are Associated with Diabetic Microvascular Disease among 9,795 Patients in the FIELD Trial

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Lipoproteins in Diabetes Mellitus

2nd ed. 2023

Volltextzugriff (PDF)

Peripheral action of spironolactone: Improvement in arterial elasticity

The American journal of cardiology, 1990-06, Vol.65 (23), p.K9-K11

1990

Volltextzugriff (PDF)

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes

Pharmacogenetics (London), 2004-12, Vol.14 (12), p.823-829

2004

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(19)

Publikationsform

Sprache

Englisch
(30)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(19)
Fenofibrate
(16)
Male
(14)
Middle Aged
(12)
Female
(11)
Fenofibrate - Therapeutic Use
(10)
Biological And Medical Sciences
(9)
Adult
(8)
Hypolipidemic Agents - Therapeutic Use
(8)
Medical Sciences
(7)
Pharmacology & Pharmacy
(7)
Cardiovascular System & Cardiology
(6)
Double-Blind Method
(6)
Fenofibrate - Administration & Dosage
(6)
Triglycerides - Blood
(6)
Cardiac & Cardiovascular Systems
(5)
Pharmacology. Drug Treatments
(5)
Aged
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans

Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?

Fenofibrate, homocysteine and renal function

Fibrates and statins in the treatment of diabetic retinopathy

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study

Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease : The Diabetes Atherosclerosis Intervention Study (DAIS)

Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy

Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?

Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes

Long-Term Effects of Fenofibric Acid + Statin Combination Therapy in Patients with High Triglycerides and Low HDL-C

Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome: A Prospective, Randomized, Double-Blind, Three-Parallel Arm, Multicenter, Comparative Study

Fibrates and microvascular complications in diabetes--insight from the FIELD study

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

LIPOPROTEIN SUBFRACTIONS ARE ASSOCIATED WITH ISCHEMIC STROKE AMONG 9,795 PATIENTS IN THE FIELD TRIAL

Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes

Abstract WP219: Lipoprotein Subfractions Are Associated With Stroke Among 9,795 Patients in the Field Trial

41-LB: Lipoprotein Subfractions Are Associated with Diabetic Microvascular Disease among 9,795 Patients in the FIELD Trial

Lipoproteins in Diabetes Mellitus

Peripheral action of spironolactone: Improvement in arterial elasticity

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes

Suchergebnisse filtern